What's Happening in the Vitiligo Pipeline?

In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.

Pearl Grimes, MD, FAAD, a Dermatology Times® board member, and Seemal R. Desai, MD, FAAD, highlight the vitiligo pipeline.

The topic of the potential treatment ruxolitinib (Opzelura; Incyte), which the FDA granted Priority Review and has a Prescription Drug User Fee Act (PDUFA) target action date is April 18, 2022, as the first FDA approved therapy for vitiligo is brought up along with the costs of this treatment. Watch the full discussion below.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.